Introduction {#s1}
============

Activation of neuronal nicotinic receptors (nAChRs) by nicotine results in increased permeability to Na^+^ and Ca^2+^ [@pone.0051154-Mulle1]. Permeability to Ca^2+^ allows for several long-term and short-term Ca^2+^-dependent processes to occur, which result in neurotransmitter release, synaptic plasticity, and upregulation of genes required for receptor synthesis [@pone.0051154-Lisman1]. These processes are thought to be important in mediating acute and chronic effects of nicotine.

Some of the targets of nicotine-induced calcium influx are Ca^2+^/calmodulin-dependent kinases, such as Ca^2+^/calmodulin-dependent kinase II (CaMKII) and Ca^2+^/calmodulin-dependent kinase IV (CaMKIV). CaMKII, a serine threonine specific kinase regulated by a Ca^2+^/calmodulin complex and abundant in brain tissue, is necessary for LTP induction, enhances synaptic transmission, and mediates neurotransmitter secretion [@pone.0051154-Lisman1]. Unlike CaMKII, CaMKIV is not as ubiquitously expressed, and is primarily found in the hippocampus, cerebellum, and amygdala, as well as in spleen, thymus, and testis [@pone.0051154-Ohmstede1], [@pone.0051154-Jones1], [@pone.0051154-Frangakis1], [@pone.0051154-Jensen1], [@pone.0051154-Takao1]. CaMKIV is also located mainly in the neuronal nuclei and is involved in the regulation of activity-triggered gene expression [@pone.0051154-Deisseroth1]. One specific transcription factor CaMKIV regulates is cyclic AMP response element binding protein (CREB) [@pone.0051154-Soderling1], which is implicated in cocaine, morphine, and nicotine reward [@pone.0051154-Carlezon1], [@pone.0051154-Walters1]. In addition, CaMKIV contributes to the activation of CREB in various memory-related areas, such as the amygdala and hippocampus [@pone.0051154-Wei1]. Using CaMKIV knockout (−/−) mice, Ko et al. [@pone.0051154-Ko1] provided evidence for a role of CaMKIV in the development of opioid analgesic tolerance but not physical dependence. Interestingly, mice lacking CaMKIV in dopaminoceptive neurons show increased sensitivity to cocaine locomotor sensitization and conditioned place preference (CPP), a reward-associated behavior, in a CREB-independent manner [@pone.0051154-Bilbao1]. However, the role of CaMKIV in nicotine's effects is unknown. Recent studies showed that CREB activation in the brain [@pone.0051154-Walters2], and more specifically, in the NAc, are critical for nicotine-induced CPP [@pone.0051154-Brunzell1]. Furthermore, changes in CREB activity in the VTA and NAc of mice were shown to accompany withdrawal in nicotine-dependent mice [@pone.0051154-Kivinummia1]. Given the proposed role of CaMKIV in CREB activation, we hypothesized that CaMKIV might be a crucial molecular component in the development of nicotine dependence. To test this hypothesis, we used CaMKIV −/− mice to elucidate the contribution of CaMKIV to nicotine dependence-like behaviors. We first assessed in the CaMKIV −/−, heterozygote (+/−), and wild-type (+/+) mice, the rewarding effects of nicotine using the CPP test. We then measured changes in CaMKIV levels in the NAc after exposure to nicotine in the CPP test. Because CREB activity is also altered after cocaine administration [@pone.0051154-Carlezon1], we tested the specificity of CaMKIV's role in nicotine behaviors by measuring cocaine CPP in genetically modified CaMKIV mice. Additionally, we assessed physical (somatic signs and hyperalgesia) and affective (anxiety-related behavior) nicotine withdrawal signs in CaMKIV mice. Finally, to assess the relevance of these behavioral changes to nicotine dependence in humans, we conducted a genetic association analysis to determine if polymorphisms in the human CaMKIV gene are associated with nicotine dependence. Our findings support a significant role for CaMKIV in nicotine and cocaine reward, as well as nicotine withdrawal, and emphasize the importance of calcium-dependent mechanisms in mediating drug-induced behaviors.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

For studies involving animal subjects, mice were group-housed in a 21°C humidity-controlled Association for Assessment and Accreditation of Laboratory Animal Care-approved animal care facility with ad libitum access to food and water. Experiments were performed during the light cycle and were approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University. Experiments were designed so that the minimum number of animals necessary to obtain concrete results were used. Animals were sacrificed by CO~2~ asphyxiation immediately following the withdrawal assessment to alleviate any suffering associated with the experiment. For all other studies, animals were sacrificed by CO~2~ asphyxiation the evening or morning following the experiment unless otherwise noted.

All datasets for human genetic association analysis were obtained via the NCBI dbGAP website <http://www.ncbi.nlm.nih.gov/gap> under a protocol approved by the Virginia Commonwealth University Institutional Review Board and the National Institutes of Health.

Animals {#s2b}
-------

Male C57Bl/6 mice and male and female breeders null for the CaMKIV gene and +/+ littermates were purchased from Jackson Laboratories (Bar Harbor, ME, USA). CaMKIV −/− and their +/+ littermates were bred in an animal care facility at Virginia Commonwealth University. For all experiments, mice were backcrossed at least 8 to 10 generations. Mutant and +/+ mice were obtained from crossing +/− mice. This breeding scheme controlled for any irregularities that might occur with crossing solely mutant animals. Animals were 8--10 weeks of age at the start of all studies.

Drugs {#s2c}
-----

(−)-Nicotine hydrogen tartrate salt and mecamylamine hydrochloride, were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). Cocaine was obtained from the National Institute on Drug Abuse (Bethesda, MD, USA). All drugs were dissolved in physiological saline (0.9% sodium chloride) at a volume of 10 ml/kg body weight. Nicotine and mecamylamine were administered subcutaneously (s.c.) and cocaine was administered intraperitoneally (i.p.). Doses are expressed as the free base of the drug.

Nicotine and Cocaine CPP {#s2d}
------------------------

Nicotine CPP (n = 8−15 per group) and cocaine CPP (n = 6−7 per group) were conducted on independent groups of CaMKIV genetically modified mice using an unbiased design as previously described by Kota et al [@pone.0051154-Kota1]. In brief, mice were handled for three days prior to initiation of CPP testing. The CPP apparatus consisted of a three-chambered box with a white compartment, a black compartment, and a center grey compartment. The black and white compartments also had different floor textures to help the mice further differentiate between the two environments. On day 1, mice were placed in the grey center compartment for a 5 min habituation period, followed by a 15 min test period to determine baseline responses. A pre-preference score was recorded and used to randomly pair each mouse with either the black or white compartment. Drug-paired sides were randomized so that an even number of mice received drug on the black and white side. Over the next 3 days, mice were conditioned twice a day, once in the morning (7--9 am) and once in the afternoon (2--4 pm), for 20 min with the saline group receiving saline on both sides of the boxes and drug groups receiving nicotine (0.5 mg/kg, s.c.) or cocaine (2.5 mg/kg, i.p.) on one side of the box and saline on the opposite side. Animals in the drug group received drug each day. Injections were counterbalanced so that some mice received drug in the morning, others in the evening. Test day (Day 5) was a drug free day, and animals were placed into the chambers similarly to day 1 procedure. Locomotor activity counts and time spent on each side were recorded, and data were expressed as time spent on the drug-paired side post-conditioning minus time spent on the drug-paired side pre-conditioning. A positive number indicated a preference for the drug-paired side, whereas a negative number indicated an aversion to the drug-paired side. A number at or near zero indicated no preference for either side.

CaMKIV Western Blot Analysis {#s2e}
----------------------------

Nicotine CPP (0.5 mg/kg) was conducted in a separate group of male C57Bl/6 mice (n = 3−5 per group). Mice were sacrificed by cervical dislocation 5 minutes after removal from the CPP chambers on test day. Brains were rapidly removed and sliced into 1 mm thick sections using a mouse brain matrix (Braintree Scientific Co., Braintree, MA, USA) on ice. The NAc, consisting of both the shell and core divisions, was identified using a stereotaxic atlas [@pone.0051154-Paxinos1] dissected from the appropriate section (approximate coordinates NAc: Bregma 1.10 mm), and homogenized immediately in cold extraction buffer containing 50 mM Tris, 1% SDS, 1 mM PMSF, 1 mM EDTA, 5 mM EGTA, 1 mM Na^+^ orthovanadate, 20 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 µM okadaic acid. Protein concentrations were determined using the Bradford assay. 30 µg of protein were incubated with 6X blue gel loading dye (New England Biolabs, Ipswich, MA, USA), and heated for 5 minutes at 95°C. Samples were then separated by SDS-polyacrylamide gel electrophoresis on a 10% TRIS-HCl gel and subjected to immunoblotting. Non-specific protein was blocked in 5% milk solution in TBS-T for 1 hour at room temperature. Primary antibodies for CaMKIV (1∶1000; Cell Signaling, Danvers, MA, USA) and α-tubulin antibody (1∶5000; Upstate, Temecula, CA, USA) were incubated overnight at 4°C. Secondary antibodies (1∶5000; LiCor Biosciences, Inc., Lincoln, NE, USA) were incubated for 1 hour at room temperature the next day. Bound antibody was detected using the LiCor Odyssey Infrared Imaging System (LiCor Biosciences, Inc., Lincoln, NE, USA). CaMKIV bands were detected at 63 kDa and α-tubulin bands were detected at 55 kDa. Blots were analyzed by taking the ratio of protein:αtubulin.

Mecamylamine-precipitated Nicotine Withdrawal Assessment {#s2f}
--------------------------------------------------------

Withdrawal studies were carried out as previously described by Jackson et al [@pone.0051154-Jackson1]. In brief, mice were anesthetized with sodium pentobarbital (45 mg/kg i.p.) and implanted with Alzet osmotic minipumps \[model 2002 (14 days); Durect Corporation, Cupertino, CA\] filled with (-)-nicotine (36 mg/kg/day) or saline solution for 14 days. The concentration of nicotine was adjusted according to animal weight and minipump flow rate. On the morning of day 15, mice (n = 4−6 per group) were injected s.c. with vehicle or 2 mg/kg mecamylamine 10 min before testing. Mice were first evaluated for 5 min in the plus maze test for anxiety-related behavior, followed by a 20 minute somatic sign observation period, during which mice were observed for paw and body tremors, head shakes, backing, jumps, curls, and ptosis. Hyperalgesia was evaluated immediately after the somatic sign observation period. This specific testing sequence is carried out based on prior studies by Jackson et al [@pone.0051154-Jackson1] showing that this order of testing results in the lowest within-group variability while producing consistent results. The number of arm crosses was also counted in the plus maze as a measure of locomotor activity.

CaMKIV Human Genetic Association Study {#s2g}
--------------------------------------

Male and female European-American subjects from the Molecular Genetics of Schizophrenia (MGS) genome wide association study and the Study of Addition: Genetics and Environment (SAGE) dataset were used to assess the possible association of polymorphisms in the CaMKIV gene with nicotine dependence. In the MGS study, only smoking data from control subjects were used in the analysis, totaling 1,819 subjects with genotype and phenotype data available. The SAGE study is comprised of three independent studies: the Collaborative Genetic Study of Nicotine Dependence (COGEND), the Collaborative Study on the Genetics of Alcoholism (COGA), and the Family Study of Cocaine Dependence (FSCD). Smoking data from each of the three studies were used in the analysis, totaling 2,150 subjects with genotype and phenotype data available for analysis. The Fagerström Test for Nicotine Dependence (FTND) scores, a categorized number of cigarettes smoked per day (numCIG) phenotype (grouped as 10 or less, 11--20, 21--30, 31 or more), and two withdrawal assessment questions from the FTND questionnaire (FTND question 1- How soon after smoking do you smoke your first cigarette?, FTND question 5- Do you smoke more cigarettes in the morning than the rest of the day?) were used as phenotypic measures of nicotine dependence. The markers rs919334, rs1457115, and rs9285875, located in the promoter region of the human CaMKIV gene, were recently found to be associated with risk for cocaine dependence [@pone.0051154-Bilbao1], thus, we chose these makers to test for an association with nicotine dependence. A linkage disequilibrium block with r-squared values for the three markers is shown in [Figure 1](#pone-0051154-g001){ref-type="fig"}. The marker rs919334 was imputed in the MGS dataset, as it was not initially genotyped. The imputation error rate was approximately 6%, indicating good imputation quality. To increase the power of our analysis, a meta-analysis was conducted using results from both datasets (n = 3,969).

![Linkage disequilibrium block containing r-squared values for the MGS and SAGE datasets combined.\
Values within the squares represent r-squared values.](pone.0051154.g001){#pone-0051154-g001}

Statistical Analysis {#s2h}
--------------------

Statistical analyses were performed using a two-way analysis of variance test for all behavioral studies with treatment and genotype as between-subject factors. One-way analysis of variance was used for the CaMKIV western blot analysis. All differences were considered significant at p\<0.05, with a Student Newman-Kuels post-hoc test used to further analyze significant results. Statistical analysis for genetic association studies was performed using the PLINK software [@pone.0051154-Purcell1]. FTND score, numCIG, and FTND question 1 (FTND1) were treated as continuous traits and were analyzed by linear regression. FTND question 5 (FTND5) was treated as a dichotomized variable and was analyzed using logistic regression. Age, sex, and principal components to control for population stratification within the sample were used as covariates. In the SAGE dataset, study (COGA,COGEND, or FSCD) was also used as a covariate.

Imputation in the MGS dataset was conducted using fastPHASE [@pone.0051154-Scheet1], with the Hapmap CEU (Utah residents with Northern and Western European ancestry) dataset as a reference panel. The GWAMA program [@pone.0051154-Magi1] was used for a meta-analysis of the results from both datasets. Cochrane's Q statistic p-values were calculated to measure between-study heterogeneity. For the haplotype analysis, the MGS and SAGE datasets were combined using the PLINK software, and principal components were generated in the combined dataset using the EIGENSTRAT software [@pone.0051154-Price1] to control for population stratification between dataset. Haplotype analysis was conducted using the proxy association feature in the PLINK software with rs919334 as the reference marker, and using age, sex, and principal components as covariates. A Bonferroni correction (p-value x no. of markers x no. of phenotypes x no. of datasets) was applied to correct for multiple testing in the meta-analysis. Uncorrected p-values are reported in the tables.

Results {#s3}
=======

Nicotine does not Induce a Significant CPP in CaMKIV −/− Mice {#s3a}
-------------------------------------------------------------

Male CaMKIV genetically modified mice were conditioned with 0.5 mg/kg nicotine for three days and preference scores were assessed. There were significant main effects of treatment \[F(~1,59~) = 21.70, p\<0.0001\], but no main effects of genotype, suggesting no significant difference between genotypes in this paradigm; however, a significant treatment x genotype interaction \[F(~2,59~) = 4.03, p\<0.05\] was detected. Results show that nicotine induced a significant CPP in CaMKIV +/+ and +/− mice; however, failed to produce a significant CPP response in CaMKIV −/− mice ([Figure 2](#pone-0051154-g002){ref-type="fig"}). CaMKIV −/− mice did not differ from saline treated CaMKIV +/+, +/−, or −/− counterparts after nicotine conditioning. No significant differences in baseline activity were observed between genotypes.

![Nicotine CPP is attenuated in CaMKIV −/− mice.\
Male CaMKIV +/+ and +/− mice develop a significant preference for nicotine (0.5 mg/kg, s.c.); however, this effect is eliminated in CaMKIV −/− mice. \*denotes p\<0.05 vs. corresponding saline groups and CaMKIV −/− nicotine group. \*\*denotes p\<0.05 vs. corresponding saline groups. Each point represents the mean ± SEM for 8--15 mice per group. The y-axis represents the preference score (drug-paired side test day -- drug paired side baseline) in seconds. The x-axis represents the treatment.](pone.0051154.g002){#pone-0051154-g002}

CaMKIV Protein Level is Significantly Increased in the NAc After Nicotine CPP {#s3b}
-----------------------------------------------------------------------------

Male C57Bl/6 mice were conditioned in the nicotine CPP paradigm (data not shown), and the NAc was dissected immediately after removal from the CPP chambers on test day to measure CaMKIV protein level after nicotine CPP. Nicotine CPP induced a significant increase in CaMKIV protein level in the NAc of mice previously conditioned with nicotine \[[Figure 3](#pone-0051154-g003){ref-type="fig"}; F(~1,6~) = 6.73, p\<0.05\]. Saline conditioning had no significant effect on CaMKIV levels.

![CaMKIV protein levels are increased after nicotine CPP.\
Brains were removed and the NAc was dissected from male C57Bl/6 mice within 5 min after removal from CPP chambers on test day. Conditioning with nicotine (0.5 mg/kg, s.c.) induced a significant increase in CaMKIV protein level in the NAc after CPP. A representative western blot is shown above the graph. Each point represents the mean ± SEM for 3--5 mice per group. The y-axis represents the percentage of saline baseline. \*denotes p\<0.05 vs. saline group.](pone.0051154.g003){#pone-0051154-g003}

Cocaine CPP is Significantly Enhanced in CaMKIV −/− Mice {#s3c}
--------------------------------------------------------

Male CaMKIV +/+, +/−, and −/− mice were conditioned with a low dose of cocaine (2.5 mg/kg, i.p.) that does not produce a significant cocaine CPP in +/+ mice. There were significant main effects of treatment \[F(~1,22~) = 23.40, p\<0.0001\], genotype \[F(~1,22~) = 7.34, p\<0.05\], and a significant genotype x treatment interaction \[F(~1,22~)\] = 12.82, p\<0.05). The dose of cocaine did not produce a significant CPP in CaMKIV +/+ or +/− mice \[CaMKIV +/− CPP scores: 40±14.31 sec\]; however, a robust CPP was observed in CaMKIV −/− mice ([Figure 4](#pone-0051154-g004){ref-type="fig"}). There were no significant differences in saline baseline between genotypes.

![Cocaine CPP is enhanced in CaMKIV −/− mice.\
Male CaMKIV +/+ mice do not develop a significant cocaine CPP after conditioning with a low cocaine dose (2.5 mg/kg, i.p.) that does not produce a significant cocaine CPP in +/+ mice; however, CaMKIV −/− mice develop a robust CPP after cocaine conditioning. Each point represents the mean ± SEM for 6--7 mice per group. \*denotes p\<0.05 vs. corresponding saline groups and CaMKIV +/+ cocaine-treated mice. The y-axis represents the preference score (drug-paired side test day -- drug paired side baseline) in seconds. The x-axis represents the treatment.](pone.0051154.g004){#pone-0051154-g004}

Affective, but not Physical Nicotine Withdrawal Signs are Altered in CaMKIV −/− Mice {#s3d}
------------------------------------------------------------------------------------

Male CaMKIV +/+ and −/− mice were chronically infused with saline or nicotine (36 mg/kg/day) through osmotic minipumps for 14 days and treated with mecamylamine (2 mg/kg, s.c.) on day 15 to precipitate nicotine withdrawal signs. Results are shown in [Figure 4](#pone-0051154-g004){ref-type="fig"}. Main effects of treatment were observed in each nicotine withdrawal test. In nicotine infused CaMKIV +/+ mice, mecamylamine precipitated significant anxiety-related behavior \[F(~2,24~) = 10.06, p\<0.001\], indicated by a decrease in the amount of time spent in the open arms of the plus maze ([Figure 5A](#pone-0051154-g005){ref-type="fig"}), increased somatic signs \[F(~2,24~) = 120.16, p\<0.0001; [Figure 5B](#pone-0051154-g005){ref-type="fig"}\], and a significant hyperalgesia response \[F(~2,24~) = 10.29, p\<0.001\], indicated by a decreased latency in the hot plate test ([Figure 5C](#pone-0051154-g005){ref-type="fig"}). For the plus maze test, there was also a significant genotype x treatment interaction \[F(~2,24~) = 5.48, p\<0.05\]. While mecamylamine induced a significant anxiety-related response in nicotine-infused CaMKIV +/+ mice, mecamylamine failed to precipitate such a response in CaMKIV −/− mice ([Figure 5A](#pone-0051154-g005){ref-type="fig"}). In contrast, mecamylamine precipitated significant somatic signs ([Figure 5B](#pone-0051154-g005){ref-type="fig"}) and hyperalgesia ([Figure 5C](#pone-0051154-g005){ref-type="fig"}) in nicotine-infused CaMKIV −/− mice, similar to that observed in +/+ mice. Results from individual somatic signs are shown in [Table 1](#pone-0051154-t001){ref-type="table"}. Interestingly, paw tremors were found to be significantly more intense in nicotine treated CamKIV −/− mice compared to +/+ counterparts \[significant main effects of treatment: F(~2,24~) = 112.04, p\<0.0001; significant main effects of genotype: F(~2,24~) = 19.60, p\<0.05; significant treatment x genotype interaction: F(~2,24~) = 11.59, p\<0.0005\], though this had no significant impact on the total average number of somatic signs, as CaMKIV −/− mice did not differ from +/+ for total somatic signs. There were no significant differences between saline CaMKIV +/+ and −/− mice in these assessments, and no significant difference in the number of arm crosses between genotypes in the plus maze test.

![CaMKIV mediates affective, but not physical nicotine withdrawal signs. A.\
Nicotine-infused CaMKIV +/+ mice show significant anxiety-like behavior after mecamylamine (2 mg/kg, s.c. at day 15) treatment in chronically infused nicotine mice (36 mg/kg/day for 14 days). Withdrawal-induced anxiety-like behaviors are reduced in nicotine-infused CaMKIV −/− mice. The y axis represents the time spent in the open arms of the plus maze in seconds. **B**. Somatic nicotine withdrawal signs are not significantly attenuated in nicotine-infused CaMKIV −/− mice compared to +/+ counterparts. The y-axis represents the average number of somatic signs observed during the 20 min session. **C.** The nicotine withdrawal-induced hyperalgesia response is observed similarly in CaMKIV +/+ and −/− mice. The y-axis represents the average hot plate latency in seconds. Each point represents the mean ± SEM of 4--6 mice per group. \*denotes p\<0.05 vs. vehicle groups. \*\*denotes p\<0.05 vs. vehicle and CaMKIV −/− nic/mec group. Veh, vehicle; mec, mecamylamine; nic, nicotine.](pone.0051154.g005){#pone-0051154-g005}

10.1371/journal.pone.0051154.t001

###### Average number of individual somatic signs assessed in CaMKIV +/+ and −/− mice.

![](pone.0051154.t001){#pone-0051154-t001-1}

  Groups                                 Paw tremor                                  Body tremor                               Head shakes                                  Backing                                     Others
  -------------------- ----------------------------------------------- ---------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------
  veh/veh CaMKIV +/+                       1.2±0.2                                        0                                      0.4±0.2                                       0                                          0
  veh/mec CaMKIV +/+                       1.2±0.7                                        0                                      0.3±0.3                                    0.5±0.3                                       0
  nic/mec CaMKIV +/+      7.2±1.1[\*](#nt102){ref-type="table-fn"}      2±0.6[\*](#nt102){ref-type="table-fn"}   5.8±2.2[\*](#nt102){ref-type="table-fn"}   2.8±1.0[\*](#nt102){ref-type="table-fn"}   0.4±0.2[\*](#nt102){ref-type="table-fn"}
  veh/veh CaMKIV −/−                       0.6±0.4                                        0                                      0.4±0.2                                       0                                          0
  veh/mec CaMKIV −/−                       1.3±0.5                                        0                                      1.75±1.1                                   0.25±0.3                                      0
  nic/mec CaMKIV −/−    12.6±0.8[\*](#nt102){ref-type="table-fn"} ^+^   2±0.5[\*](#nt102){ref-type="table-fn"}                   2.6±0.2                    2.8±0.3[\*](#nt102){ref-type="table-fn"}   0.4±0.4[\*](#nt102){ref-type="table-fn"}

Each point represents the mean ± SEM of 4--6 mice per group. The heading "others" refers to jumps, curls, and ptosis.

denotes p\<0.05 vs. corresponding vehicle groups. + denotes p\<0.05 vs. CamKIV nic/mec +/+ mice. veh, vehicle; nic, nicotine; mec, mecamylamine.

Variants in CaMKIV are Associated with Nicotine Dependence Phenotypes {#s3e}
---------------------------------------------------------------------

Our animal data suggests that CaMKIV is involved in nicotine-mediated behaviors. To support these findings, we tested the markers rs919334, rs1457115, and rs9285875**,** located within the promoter region of the CaMKIV gene, for an association with nicotine dependence in two independent datasets and conducted a meta-analysis of the results. Results are shown in [Table 2](#pone-0051154-t002){ref-type="table"}. Cochrane's Q statistic p-values were significant for the rs919334 marker in the FTND phenotype (p = 0.02) and marginal for the FTND1 phenotype (p = 0.06). Thus, a random effects meta-analysis was used to analyze the data to account for possible heterogeneity between datasets. The marker rs919334 was significantly associated with a protective effect in the FTND analysis, suggesting an association with lower FTND scores. Interestingly, the marker rs9285875 was associated with risk for higher FTND scores. Neither marker survived correction for multiple testing.

10.1371/journal.pone.0051154.t002

###### Variants in the CaMKIV gene are associated with nicotine dependence.

![](pone.0051154.t002){#pone-0051154-t002-2}

  Phenotype             SNP             Allele        P-value            Beta/OR           Q p-value
  ------------ ---------------------- ---------- ----------------- ------------------- -----------------
  **FTND**      **[rs919334]{.ul}**    [C]{.ul}   **[0.01]{.ul}**   **−[0.185]{.ul}**   **[0.41]{.ul}**
                     rs1457115            A            0.53              −0.044              0.51
                **[rs9285875]{.ul}**   [T]{.ul}   **[0.04]{.ul}**   **[0.163]{.ul}**    **[0.82]{.ul}**
  **numCIG**          rs919334            C            0.17              −0.034              0.20
                     rs1457115            A            0.95              −0.001              0.45
                     rs9285875            T            0.43               0.021              0.88
  **FTND1**           rs919334            C            0.14              −0.045              0.06
                     rs1457115            A            0.11               0.046              0.86
                     rs9285875            T            0.63              −0.015              0.56
  **FTND5**           rs919334            C            0.33               0.94              *0.02*
                     rs1457115            A            0.50               1.04               0.72
                     rs9285875            T            0.87               1.01               0.08

Human genetic association meta-analysis using two datasets (SAGE and MGS, n = 3,969). The variant rs919334 is associated with a protective effect in the FTND score analysis, while rs9285875 is associated with risk for higher FTND scores. The table contains uncorrected p-values, where significant p- values are bolded and underlined. No markers survived correction for multiple testing. Significant Q p-values are italicized. SNP, single nucleotide polymorphism; the Allele column represents the minor allele; Q p-values represent Cochrane's Q-statistic p-values.

Based on these findings, we conducted a haplotype analysis using the combined MGS and SAGE dataset and markers \[rs919334-rs1457115-rs9285875\] ([Table 3](#pone-0051154-t003){ref-type="table"}). We found significant multi-marker combinations for FTND score, numCIG, and FTND5. The C-G-T haplotype consisting of both the protective rs919334 allele and the risk rs9285875 allele represented a significant protective haplotype for FTND score, numCIG (corrected p = 0.002) and FTND5 (corrected p = 0.0002). Similar protective effects were observed with the T-G-C haplotype for FTND, numCIG (corrected p = 0.005), and FTND5 (corrected p = 0.0005), which consists of the major alleles from each marker, and for C-A-C for FTND scores. Alternatively, the T-G-T haplotype consisting of the minor risk allele for rs9285875 confers risk for higher FTND scores, smoking more cigarettes per day (numCIG), and smoking more in the morning than any other time of day (FTND5), though none of these associations survived correction for multiple testing.

10.1371/journal.pone.0051154.t003

###### Haplotype analysis of the three CaMKIV variants.

![](pone.0051154.t003){#pone-0051154-t003-3}

  Phenotype           Haplotype                                P-value                               Beta/OR
  ------------ ----------------------- ------------------------------------------------------- -------------------
  **FTND**      **[CGT (0.03)]{.ul}**                      **[0.04]{.ul}**                      **−[0.497]{.ul}**
                **[TGT (0.24)]{.ul}**                      **[0.02]{.ul}**                      **[0.212]{.ul}**
                **[CAC (0.08)]{.ul}**                     **[0.005]{.ul}**                      **−[0.377]{.ul}**
                     TAC (0.37)                                 0.16                                  0.109
                     CGC (0.23)                                 0.97                                 −0.004
                **[TGC (0.05)]{.ul}**                      **[0.02]{.ul}**                      **−[0.393]{.ul}**
  **numCIG**       **[CGT]{.ul}**        **[0.0001]{.ul}** [\*](#nt105){ref-type="table-fn"}    **−[0.319]{.ul}**
                   **[TGT]{.ul}**                          **[0.02]{.ul}**                      **[0.068]{.ul}**
                         CAC                                    0.06                                 −0.087
                         TAC                                    0.18                                  0.035
                         CGC                                    0.45                                  0.023
                   **[TGC]{.ul}**        **[0.0002]{.ul}** [\*](#nt105){ref-type="table-fn"}    **−[0.212]{.ul}**
  **FTND1**              CGT                                    0.19                                 −0.128
                         TGT                                    0.92                                 −0.004
                         CAC                                    0.81                                 −0.015
                         TAC                                    0.05                                  0.070
                         CGC                                    0.14                                 −0.061
                         TGC                                    0.92                                 −0.007
  **FTND5**        **[CGT]{.ul}**       **[1.21E-05]{.ul}** [\*](#nt105){ref-type="table-fn"}    **[0.63]{.ul}**
                   **[TGT]{.ul}**                          **[0.01]{.ul}**                       **[1.20]{.ul}**
                         CAC                                    0.07                                  0.81
                         TAC                                    0.21                                  1.08
                         CGC                                    0.08                                  1.14
                   **[TGC]{.ul}**       **[1.61E-05]{.ul}** [\*](#nt105){ref-type="table-fn"}    **[0.73]{.ul}**

Haplotypes are presented as rs919334-rs1457115-rs9285875. The frequency of each haplotype is in parenthesis next to the haplotype in the FTND phenotype row. Uncorrected significant p-values are bolded and underlined.

denotes p-values that survived correction for multiple testing.

Discussion {#s4}
==========

The goal of the current study was to elucidate the role of CaMKIV in nicotine dependence behaviors using both animal models and genetic association analysis. Results show that in CaMKIV −/− mice, nicotine CPP is attenuated, but cocaine CPP is enhanced. CaMKIV protein levels are also increased in the NAc after nicotine CPP. Further, anxiety-related behavior is not observed in CaMKIV −/− mice after precipitated nicotine withdrawal; however, somatic signs and the hyperalgesia response are not affected. We also identified variants and haplotypes in the promoter region of the CaMKIV gene associated with nicotine dependence. Findings from this study indicate the possibility of opposing roles for CaMKIV in nicotine and cocaine reward, and suggest that CaMKIV is involved in mediating affective, but not physical nicotine withdrawal behaviors. Significant association analyses further support the potential relevance of our findings to nicotine dependence in humans.

In the nicotine CPP assessment, the robust CPP observed in CaMKIV +/+ mice was significantly attenuated in CaMKIV −/− mice. CaMKIV protein levels were also increased in the NAc after nicotine CPP in C57Bl/6 mice. Similarly, pCREB levels were increased in the NAc and NAc shell after nicotine CPP [@pone.0051154-Walters2], [@pone.0051154-Brunzell1], while nicotine CPP was blocked by disruption of the CREB gene using CREB^αΔ^ mice [@pone.0051154-Walters2] and by targeted disruption of CREB activation in the NAc shell [@pone.0051154-Brunzell1]. CaMKIV phosphorylates CREB at Ser133 in the nuclei of neurons [@pone.0051154-Soderling1], [@pone.0051154-Deisseroth2]. While there are certainly other pathways that mediate CREB phosphorylation, such as extracellular regulated protein kinase, the current results suggest a possible contribution of the CaMKIV/CREB pathway in the NAc in processes involved in nicotine reward.

Conversely, cocaine CPP was enhanced in CaMKIV −/− mice, the opposite of that observed in the nicotine CPP assessment. These results are similar to those reported recently by Bilbaoa et al. [@pone.0051154-Bilbao1] who showed that mice lacking CaMKIV in dopaminoceptive neurons displayed increased sensitivity to cocaine CPP. It is unlikely that differences in learning and memory attribute to these contrasting results, as CaMKIV −/− display normal spatial and learning memory [@pone.0051154-Takao1]. Cocaine has been shown to regulate CREB in the NAc [@pone.0051154-Carlezon1]. While overexpression of CREB in the NAc produced aversion to low doses of cocaine, overexpression of a dominant-negative mutant CREB increased the rewarding effects of cocaine [@pone.0051154-Carlezon1]. Similar behavior was obeserved in CREB^αΔ^ which lack the major CREB isoforms [@pone.0051154-Walters1]. Despite the studies implicating a connection in cocaine reward between CaMKIV and CREB in the NAc, inactivation of CaMKIV in dopaminoceptive neurons, including neurons in the NAc, enhanced cocaine CPP in a CREB-independent manner [@pone.0051154-Bilbao1]. Thus, in the case of nicotine, while we cannot rule out the possible involvement of the CaMKIV/CREB pathway in nicotine reward, with cocaine, the involvement of CaMKIV appears to be independent of CREB, a finding that may contribute to the observed differences between the role of CaMKIV in nicotine and cocaine reward.

In the withdrawal assessment, the anxiety-related response was attenuated in CaMKIV −/− mice, but there was no significant difference between genotypes in either physical nicotine withdrawal measure, suggesting that CaMKIV has a role in mediating affective, but not physical nicotine withdrawal behaviors. While it is noted that paw tremors were significantly enhanced in CaMKIV −/− mice compared to +/+, the implications of which are unclear, these observations did not significantly impact the overall total average somatic signs, thus maintaining our hypothesis that CaMKIV is not involved in this aspect of nicotine withdrawal. Though we did not observe differences in anxiety-related behavior between vehicle treated CaMKIV +/+ and −/− mice, it has been reported that CaMKIV −/− mice exhibit decreased anxiety-like behavior based on the light/dark transition and elevated plus maze tests [@pone.0051154-Takao1], [@pone.0051154-Shum1]. These differences may be attributed to stress as a result of mini pump implantation surgery and subsequent saline mini pump infusion in our study, which may have impacted our results. Results may also be attributed to differences in the breeding generation of mice used between studies. Thus, our results in this assessment are interpreted with caution, as we cannot rule out the possible contribution of the anxiolytic-like phenotype observed in CaMKIV −/− mice.

Similar results were observed in a previous study from our lab with CaMKII +/− mice, where there was a loss of anxiety-related behavior, but physical withdrawal signs were present [@pone.0051154-Jackson2]. Interestingly, the current results are the opposite of that observed with the CaMKII inhibitor, KN-93, which was shown to enhance nicotine withdrawal-induced anxiety related behavior and block somatic signs [@pone.0051154-Jackson2]. KN93 blocks both CaMKII and CaMKIV activity [@pone.0051154-Hook1], and it was suspected that the discrepancy between our previous CaMKII genetic and pharmacological data was due to KN-93 activity at CaMKIV [@pone.0051154-Jackson2]; however, the current results refute this notion. It is also possible that CaMKII +/− mice, which still possess 50% of the enzyme activity, do not have sufficient loss of activity to induce alterations that contribute to the observed behaviors after nicotine withdrawal. Further, these two enzymes may simply have differential involvement in mediating nicotine withdrawal behaviors.

Because affective nicotine withdrawal signs, which are hypothesized to contribute more to relapse than somatic signs [@pone.0051154-Koob1], [@pone.0051154-Markou1], were attenuated in CaMKIV −/− mice, these results suggest that CaMKIV levels are increased after withdrawal from nicotine, and reducing CaMKIV gene expression alleviates certain aspects of nicotine dependence. Indeed, pCREB and CREB levels were increased in the VTA and NAc respectively, after nicotine withdrawal [@pone.0051154-Brunzell2]. While in the current study, we did not test the conditioned place aversion model, an additional affective measure of nicotine withdrawal, increased CREB activity in the NAc produces conditioned place aversion in mice [@pone.0051154-Barrot1]. CaMKIV in the NAc also modulates emotional behavior in mice [@pone.0051154-Schneider1]. As observed in our reward assessment, we propose that these studies support a role for CaMKIV in affective withdrawal measures, and taken together with previous reports, may implicate involvement of the CaMKIV/CREB pathway in the NAc.

Results from our human genetic association study support the animal data from our withdrawal assessment, implicating genetic variation in the CaMKIV gene promoter in nicotine dependence. Specifically, the rs919334 polymorphism is associated with a protective effect against nicotine dependence, based on lower FTND scores, while the rs9285875 polymorphism is associated with risk for higher FTND scores. While these findings initially appear to conflict, our multi-marker haplotype analysis was consistent with our single marker analysis, revealing that the presence of the minor alleles for both of these markers in combination (C-G-T) represents a significant protective haplotype against higher FTND scores, smoking a higher number of cigarettes per day, and smoking more cigarettes in the morning, while the T-G-T combination, consisting of the minor rs9285875 risk allele and the major risk alleles for the other two markers represents significant risk for higher FTND scores, smoking more cigarettes per day, and smoking more cigarettes in the morning. These results indicate that the haplotype analysis was more powerful in detecting significant associations with our smoking phenotypes than the single marker analysis, as we were able to detect significant associations with numCIG and FTND5 that were not evident in our single marker analysis, as well as obtain lower p-values that survived correction for multiple testing. Our genetic findings identify protective haplotypes that potentially reflect a reduced risk of developing nicotine dependence and a less severe withdrawal syndrome. Coinciding with our behavioral results, attenuated rewarding effects of nicotine and alleviation of affective nicotine withdrawal behaviors in CaMKIV −/− mice may also reflect protective mechanisms against development or maintenance of nicotine dependence. Further, because these variants are located in the promoter region of the CaMKIV gene, it is possible that they affect gene expression. Similar to the findings from our CPP assessments, these results are the opposite of that observed for cocaine, where rs919334 was associated with risk for cocaine addiction [@pone.0051154-Bilbao1]. Interestingly, a similar effect was observed with the nonsynonymous polymorphism, rs16969968, located in the α5 nAChR gene, which is associated with risk for nicotine dependence, but protective against cocaine dependence [@pone.0051154-Grucza1]. The current results further support the hypothesis that such bidirectional associations between nicotine and cocaine dependence stem from the involvement of nAChRs in modulating both excitatory and inhibitory dopamine-mediated reward pathways [@pone.0051154-Grucza1], which may in turn differentially regulate downstream calcium-dependent processes. While additional studies are necessary to determine if these CaMKIV variants do indeed influence gene expression, we hypothesize that increased CaMKIV gene expression exerts a protective effect in nicotine dependence, but enhances the risk for cocaine dependence.

Our findings from the current study identify a calcium-dependent protein, a relevant brain region, and genetic haplotypes involved in nicotine dependence behaviors. Specifically, our studies support an important role for CaMKIV in mediating nicotine reward, and suggest that increased CaMKIV protein levels in the NAc influence this behavior. Our results further implicate a role for the protein in nicotine withdrawal behaviors. Further, we show that the findings in our reward study extend to cocaine, as alterations in the CaMKIV gene also mediate cocaine reward, though the role is the opposite of that observed with nicotine. Lastly, we support our studies with human genetic association, showing that variation in the CaMKIV gene is protective against nicotine dependence, a finding also opposite of that found in cocaine studies assessing CaMKIV gene variation. Overall, these studies further indicate the importance of calcium-dependent mechanisms in drug-mediated behaviors.
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